{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:55:48Z","timestamp":1781535348222,"version":"3.54.5"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Predicting axillary pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) may enable risk-adapted axillary management in clinically node-positive breast cancer (BC), but practical baseline PET-derived predictors are limited.<\/jats:p>\n                  <jats:p>Single-center retrospective cohort of consecutive cN+, M0 patients with baseline [18F]FDG PET\/CT\u2013reported axillary nodal metastasis treated with NST and surgery (complete-case n=115). Axillary pCR was defined as no residual invasive carcinoma in axillary lymph nodes; isolated tumor cells and\/or micrometastases were classified as non-pCR. Two prespecified ridge-penalized logistic models combined routine clinical variables with baseline PET-defined axillary burden as (i) hypermetabolic ALN count (Model A) or (ii) limited (1\u20133) versus advanced (\u22654) burden group (Model B). Stratified 5-fold cross-validation generated out-of-fold (OOF) predictions; AUC, Brier score, and logistic recalibration slope\/intercept were bootstrapped on OOF predictions (2000 resamples).<\/jats:p>\n                  <jats:p>Axillary pCR occurred in 59\/115 (51.3%). Discrimination was good: AUC 0.80 (95% CI 0.72\u20130.88) for Model A and 0.79 (95% CI 0.71\u20130.87) for Model B. Calibration was acceptable (bootstrap-mean slope\/intercept \u22481.10\/0.04 and 1.08\/0.03, respectively). Greater baseline PET-defined axillary extent was associated with lower odds of pCR; molecular subtype and neoadjuvant anti-HER2 therapy remained strongly associated with response.<\/jats:p>\n                  <jats:p>Prespecified ridge models combining routine clinical variables with baseline [18F]FDG PET\/CT\u2013defined axillary burden showed good internal performance for predicting axillary pCR. External validation is required before response-adapted clinical use.<\/jats:p>","DOI":"10.1055\/a-2825-4883","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:50:14Z","timestamp":1779403814000},"page":"207-216","source":"Crossref","is-referenced-by-count":0,"title":["Baseline FDG PET\/CT\u2013Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer"],"prefix":"10.1055","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-4973","authenticated-orcid":false,"given":"Mehmet Tar\u0131k","family":"Tato\u011flu","sequence":"additional","affiliation":[{"name":"TC Saglik Bakanligi Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, T\u00fcrkiye","place":["Istanbul"],"department":["Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lker Nihat","family":"\u00d6kten","sequence":"additional","affiliation":[{"name":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 G\u00f6ztepe Prof Dr S\u00fcleyman Yal\u00e7\u0131n \u015eehir Hastanesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of Medical Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Ibisoglu","sequence":"additional","affiliation":[{"name":"G\u00f6ztepe Prof Dr S\u00fcleyman Yal\u00e7\u0131n \u015eehir Hastanesi, T\u00fcrkiye","place":["Istanbul"],"department":["Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u00e7e","family":"S\u00f6ylemez Akkurt","sequence":"additional","affiliation":[{"name":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 G\u00f6ztepe Prof Dr S\u00fcleyman Yal\u00e7\u0131n \u015eehir Hastanesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of Pathology"]},{"name":"\u0130stanbul Medeniyet \u00dcniversitesi Tip Fak\u00fcltesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of Pathology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferda","family":"Yerdelen Tato\u011flu","sequence":"additional","affiliation":[{"name":"Istanbul University Faculty of Economics, T\u00fcrkiye","place":["Istanbul"],"department":["Department of Econometrics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Uslu","sequence":"additional","affiliation":[{"name":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 G\u00f6ztepe Prof Dr S\u00fcleyman Yal\u00e7\u0131n \u015eehir Hastanesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of Nuclear Medicine"]},{"name":"\u0130stanbul Medeniyet \u00dcniversitesi Tip Fak\u00fcltesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Baysal","sequence":"additional","affiliation":[{"name":"TC Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 G\u00f6ztepe Prof Dr S\u00fcleyman Yal\u00e7\u0131n \u015eehir Hastanesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of General Surgery"]},{"name":"\u0130stanbul Medeniyet \u00dcniversitesi Tip Fak\u00fcltesi, T\u00fcrkiye","place":["Istanbul"],"department":["Department of General Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-013-2678-8","article-title":"Pre-chemotherapy 18F-FDG PET\/CT upstages nodal stage in stage II\u2013III breast cancer patients treated with neoadjuvant chemotherapy","volume":"141","author":"BB Koolen","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"09","key":"ref4","doi-asserted-by":"publisher","first-page":"znae203","DOI":"10.1093\/bjs\/znae203","article-title":"Disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer","volume":"111","author":"FJG van Amstel","year":"2024","journal-title":"Br J Surg"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1634\/theoncologist.2019-0583","article-title":"Subtype-guided 18F-FDG PET\/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: a feasibility study","volume":"25","author":"S Wu","year":"2020","journal-title":"Oncologist"},{"issue":"06","key":"ref6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00259-011-1735-y","article-title":"FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients","volume":"38","author":"C Rousseau","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00259-013-2657-7","article-title":"Early and delayed prediction of axillary lymph node neoadjuvant response by 18F-FDG PET\/CT in patients with locally advanced breast cancer","volume":"41","author":"AM Garc\u00eda Vicente","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"ref8","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00259-011-1921-y","article-title":"Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?","volume":"38","author":"L Gilardi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00259-013-2515-7","article-title":"Sequential 18F-FDG PET\/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy","volume":"41","author":"BB Koolen","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"30","key":"ref10","doi-asserted-by":"publisher","first-page":"29388","DOI":"10.18632\/oncotarget.5001","article-title":"18F-fluorodeoxyglucose PET\/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive, breast cancer","volume":"6","author":"J Cheng","year":"2015","journal-title":"Oncotarget"},{"issue":"08","key":"ref11","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00259-014-2739-1","article-title":"HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy","volume":"41","author":"O Humbert","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO","volume":"54","author":"G Gebhart","year":"2013","journal-title":"J Nucl Med"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40644-017-0117-5","article-title":"Additional value of 18F-FDG PET\/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer","volume":"17","author":"MS van Ramshorst","year":"2017","journal-title":"Cancer Imaging"},{"issue":"06","key":"ref14","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1245\/s10434-018-6404-y","article-title":"Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure","volume":"25","author":"MEM van der Noordaa","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13550-021-00824-4","article-title":"[18F]FDG-PET\/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy","volume":"11","author":"AA van Loevezijn","year":"2021","journal-title":"EJNMMI Res"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/diagnostics11122361","article-title":"Efficacy of US, MRI, and 18F-FDG PET\/CT for detecting axillary lymph node metastasis after neoadjuvant chemotherapy in breast cancer patients","volume":"11","author":"U Turan","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"02","key":"ref17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00259-017-3823-0","article-title":"Added value of dedicated axillary hybrid 18F-FDG PET\/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study","volume":"45","author":"TJA van Nijnatten","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"07","key":"ref18","first-page":"e490","article-title":"Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid 18F-FDG PET\/MRI in clinically node-positive breast cancer patients: a pilot study","volume":"77","author":"CM de Mooij","year":"2022","journal-title":"Clin Radiol"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/cancers15020401","article-title":"Prediction of primary tumour and axillary lymph node response to neoadjuvant chemo(targeted) therapy with dedicated breast 18F-FDG PET\/MRI in breast cancer","volume":"15","author":"CM de Mooij","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"03","key":"ref20","first-page":"220","article-title":"The role of basal metabolic and volumetric 18F-FDG PET\/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy","volume":"25","author":"F Kepenek","year":"2022","journal-title":"Hellenic J Nucl Med"},{"issue":"03","key":"ref21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MNM.0000000000001332","article-title":"The role of basal 18F-FDG PET\/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients receiving neoadjuvant chemotherapy","volume":"42","author":"N Akdeniz","year":"2021","journal-title":"Nucl Med Commun"},{"issue":"04","key":"ref22","first-page":"210","article-title":"The prognostic role of baseline 18F-FDG PET\/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy","volume":"40","author":"C Can","year":"2021","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.3390\/cancers14235869","article-title":"The value of semiquantitative parameters derived from 18F-FDG PET\/CT for predicting response to neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer","volume":"14","author":"L Urso","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"02","key":"ref24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4274\/mirt.galenos.2022.44154","article-title":"The value of 18F-FDG PET\/CT imaging in the evaluation of interim neoadjuvant chemotherapy response in locally advanced breast cancer","volume":"31","author":"G Tatar","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.3390\/cancers15102715","article-title":"18F-FDG PET-derived volume-based parameters to predict disease-free survival in patients with grade III breast cancer of different molecular subtypes candidates to neoadjuvant chemotherapy","volume":"15","author":"N Quartuccio","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"ref26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/MNM.0000000000001074","article-title":"Metabolic and volume-based parameters of 18F-FDG PET\/CT for primary mass and axillary lymph node metastasis in invasive ductal carcinoma: relation to molecular subtype and immunohistochemistry","volume":"40","author":"C Can","year":"2019","journal-title":"Nucl Med Commun"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"S Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","article-title":"Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy","volume":"271","author":"S Samiei","year":"2020","journal-title":"Ann Surg"},{"issue":"04","key":"ref29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","article-title":"Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis","volume":"273","author":"S Samiei","year":"2021","journal-title":"Ann Surg"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1634\/theoncologist.2015-0353","article-title":"FDG-PET\/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies","volume":"21","author":"S Sheikhbahaei","year":"2016","journal-title":"Oncologist"},{"issue":"11","key":"ref31","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1007\/s00330-017-4831-y","article-title":"The accuracy of 18F-FDG PET\/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review","volume":"27","author":"F Tian","year":"2017","journal-title":"Eur Radiol"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2025.2752","article-title":"Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer","volume":"11","author":"AKE van Hemert","year":"2025","journal-title":"JAMA Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104411","article-title":"Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol","volume":"80","author":"AKE van Hemert","year":"2025","journal-title":"Breast"},{"issue":"01","key":"ref34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","article-title":"Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol","volume":"193","author":"AA van Loevezijn","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"07","key":"ref35","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s00259-019-04313-8","article-title":"PET\/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy","volume":"46","author":"L Antunovic","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s00259-020-04684-3","article-title":"18F-FDG PET\/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients","volume":"47","author":"P Li","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/cancers14071727","article-title":"Multiparametric 18F-FDG PET\/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer","volume":"14","author":"L Umutlu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"05","key":"ref38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2967\/jnumed.123.266384","article-title":"Optimal [18F]FDG PET\/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial","volume":"65","author":"G Gebhart","year":"2024","journal-title":"J Nucl Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104475","article-title":"Impact of routine FDG-PET\/CT on locoregional treatment decisions in breast cancer patients receiving preoperative systemic therapy","volume":"81","author":"JLB Gunster","year":"2025","journal-title":"Breast"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2825-4883.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:42:47Z","timestamp":1781534567000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2825-4883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":37,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2825-4883","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}